Table 2 Correlation between expression of AT1R and MDK and clinicopathological factors of HNSCC
From: Prognosis of Midkine and AT1R expression in resectable head and neck squamous cell carcinoma
No. of patients | AT1R | P | MDK | P | |||
|---|---|---|---|---|---|---|---|
Weak expression | Strong expression | Weak expression | Strong expression | ||||
Age | 0.226 | 0.599 | |||||
≦51 | 76 | 43 (56.6%) | 33 (43.4%) | 43 (56.6%) | 33 (43.4%) | ||
 > 51 | 74 | 49 (66.2%) | 25 (33.8%) | 45 (60.8%) | 29 (39.2%) | ||
Gender | 0.944 | 0.141 | |||||
Male | 142 | 87 (61.3%) | 55 (38.7%) | 81 (57.0%) | 61 (43.0%) | ||
Female | 8 | 5 (62.5%) | 3 (37.5%) | 7 (87.5%) | 1 (12.5%) | ||
ECOG PS | 0.087 | 0.072 | |||||
0 | 55 | 40 (72.7%) | 15 (27.3%) | 37 (67.3%) | 18 (32.7%) | ||
1 | 68 | 38 (55.9%) | 30 (44.1%) | 40 (58.8%) | 28 (41.2%) | ||
2 | 27 | 14 (51.9%) | 13 (48.1%) | 11 (40.7%) | 16 (59.3%) | ||
Tumor site | 0.182 | 0.249 | |||||
Oral cavity | 98 | 64 (65.3%) | 34 (37.4%) | 62 (63.3%) | 36 (36.7%) | ||
Oropharynx | 24 | 15 (62.5%) | 9 (37.5%) | 13 (54.2%) | 11 (45.8%) | ||
Hypopharynx/larynx | 28 | 13 (46.4%) | 15 (53.6%) | 13 (46.4%) | 15 (53.6%) | ||
AJCC tumor stage | 0.001** | 0.004** | |||||
I–III | 59 | 45 (76.3%) | 14 (23.7%) | 43 (72.9%) | 16 (27.1%) | ||
IVA–B | 91 | 47 (51.6%) | 44 (48.4%) | 45 (49.5%) | 46 (50.5%) | ||
T stage | 0.303 | 0.424 | |||||
1–3 | 88 | 57(64.8%) | 31(35.2%) | 54 (61.4%) | 34 (38.6%) | ||
4A–B | 62 | 35 (56.5%) | 27 (43.5%) | 34 (54.8%) | 28 (45.2%) | ||
N stage | 0.423 |  < 0.001** | |||||
Negative | 63 | 41(65.1%) | 22(34.9%) | 50 (79.4%) | 13 (20.6%) | ||
Positive | 87 | 51 (58,6%) | 36 (41.4%) | 38 (43.7%) | 49 (56.3%) | ||
P16 expression | 0.405 | 0.324 | |||||
Negative | 131 | 82 (62.6%) | 49 (37.4%) | 79 (60.3%) | 52 (39.7%) | ||
Positive | 19 | 10 (52.6%) | 9 (47.4%) | 9 (47.4%) | 10 (52.6%) | ||
ENE | 0.001** |  < 0.001** | |||||
Negative | 104 | 73 (70.2%) | 31 (29.8%) | 75 (72.1%) | 29 (27.9%) | ||
Positive | 46 | 19 (41.3%) | 27 (58.7%) | 13 (28.3%) | 33 (71.7%) | ||
LVI 0.759 | 0.814 | ||||||
Negative | 96 | 58 (60.4%) | 38 (39.6%) | 57 (59.4%) | 39 (40.6%) | ||
Positive | 54 | 34 (63.0%) | 20 (37.0%) | 31 (57.4%) | 23 (42.6%) | ||
PNI 0.435 | 0.622 | ||||||
Negative | 81 | 52 (64.2%) | 29 (35.8%) | 49 (60.5%) | 32 (39.5%) | ||
Positive | 69 | 40 (58.0%) | 29 (42.0%) | 39 (56.5%) | 30 (43.5%) | ||
Alcohol drinking | 0.065 | 0.127 | |||||
No | 44 | 32 (72.7%) | 12 (27.3%) | 30 (68.2%) | 14 (31.8%) | ||
Yes | 106 | 60 (56.6%) | 46 (43.4%) | 58 (54.7%) | 48 (45.3%) | ||
Smoking | 0.276 | 0.562 | |||||
No | 30 | 21 (70.0%) | 9 (30.0%) | 19 (63.3%) | 11 (36.7%) | ||
Yes | 120 | 71(59.2%) | 49 (40.8%) | 69 (57.5%) | 51(42.5%) | ||
Betel nuts | 0.651 | 0.075 | |||||
No | 51 | 30 (58.8%) | 21 (41.2%) | 35 (68.6%) | 16 (31.4%) | ||
Yes | 99 | 62 (62.6%) | 37 (37.4%) | 53 (53.5%) | 46 (46.5%) | ||
DM | 0.132 | 0.525 | |||||
Negative | 94 | 62 (66.0%) | 32 (34.0%) | 57 (60.6%) | 37 (39.4%) | ||
Positive | 56 | 30 (53.6%) | 26 (46.4%) | 31 (55.4%) | 25 (44.6%) | ||
Hypertension | 0.004** | 0.242 | |||||
No | 69 | 52 (75.4%) | 17 (24.6%) | 44 (63.8%) | 25 (36.2%) | ||
Yes | 81 | 40 (49.4%) | 41 (50.6%) | 44 (54.3%) | 37 (45.7%) | ||
Viral hepatitis | 0.236 | 0.348 | |||||
No | 100 | 58 (58.0%) | 42 (42.0%) | 56 (56.0%) | 44 (44.0%) | ||
Yes | 50 | 34 (68.0%) | 16 (32.0%) | 32 (64.0%) | 18 (36.0%) | ||
MDK |  < 0.001** | ||||||
Weak | 88 | 66 (75.0%) | 22 (25.0%) | ||||
Strong | 62 | 26 (41.9%) | 36 (58.1%) | ||||
AT1R |  < 0.001** | ||||||
Weak | 92 | 67 (72.8%) | 25 (27.2%) | ||||
Strong | 58 | 21 (36.2%) | 37 (63.8%) | ||||